Washington Area Comprehensive Sickle Cell Center

华盛顿地区综合镰状细胞中心

• 批准号: 8135101
• 负责人: Victor R Gordeuk
• 金额: $ 3.8万
• 依托单位: HOWARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-18 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8135101
• 关键词: AIDS/HIV problem; Adhesions; Adult; Advisory Committees; Affect; Age; Angiotensin-Converting Enzyme Inhibitors; Apolipoprotein A-I; Area; Blood Pressure; Blood Transfusion; Blood Vessels; Candidate Disease Gene; Capital; Child; Childhood; Clinic; Clinical; Clinical Research; Clinical Treatment; Collaborations; Communities; Community Outreach; Development; Development Plans; Diagnostic tests; Doctor of Philosophy; Education; Educational process of instructing; Endothelium; Family; Functional disorder; Genetic Counseling; Genetic Polymorphism; Glass; Health Personnel; Health Professional; Health Services Research; High Density Lipoproteins; Human Resources; Hypertension; Infant; Infection; Institution; Investigation; Iron; Kidney; Maintenance; Malaria; Martes zibellina; Measurement; Medical center; Medicine; Mentors; Modeling; National Heart, Lung, and Blood Institute; Neurodevelopmental Deficit; Nicotinic Acids; Nigeria; Nitric Oxide; Patients; Placebos; Prevalence; Prevention; Pulmonary Hypertension; Rana; Relative (related person); Research; Research Design; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Role; Services; Sickle Cell; Sickle Cell Anemia; Stroke; Toddler; Translational Research; Universities; Vasodilation; Washington; Work; career development; clinical care; data management; data sharing; dissemination research; hydroxyurea; improved; investigator training; phase 2 study; prevent; programs; pulmonary arterial hypertension; research study; web site

DESCRIPTION (provided by applicant): The proposed Washington Area Comprehensive Sickle Cell Center includes Howard University, a historically-black teaching institution in the nation's capital, Children's National Medical Center, the premier provider of healthcare to children with sickle cell disease (SCD) in the area, and the Vascular Medicine Branch of NHLBI, an internationally recognized unit that leads in the investigation of the vascular complications of SCD. The proposed Center also includes collaboration with Ahmadu Bello University in Zaria, Nigeria, an institution that treats many SCD patients who have not yet been exposed to blood transfusions or hydroxyurea. The primary focus of the proposed center is to improve understanding, prevention and treatment of the vascular complications of SCD. The components of the project are: 1. An inter-Center Phase II Study of therapy with a nitric oxide-donating combination compared to an angiotensin converting enzyme inhibitor or placebo in preventing renal dysfunction, pulmonary hypertension, stroke and other complications in SCD patients with systemic systolic blood pressure of 120-139 mm Hg. 2. An intra-Center clinical study to determine the prevalence of pulmonary hypertension in Nigerian SCD patients using echocardiographic measurements of the tricuspid regurgitant jet velocity, the contribution of HIV/AIDS and malaria, and the role of genetic polymorphisms in candidate genes that regulate endothelial function and adhesion. 3. A patient services research project to identify the prevalence of developmental problems among infants and toddlers with SCD compared to age and demographically matched controls. 4. A translational research project that seeks to raise levels of HDL and therefore apoA-1 to improve endothelium-dependent vasorelaxation by administration of the NAD precursor, niacin. 5. An Administrative Core. 6. A Clinical Core that includes the adult and pediatric sickle cell clinics at Howard University, the pediatric sickle cell clinic at Children's National Medical Center, the adult sickle cell clinic at NHLBI, and their associated personnel. 7. A Patient Services Core focusing on education, community outreach, genetic counseling and diagnostic testing. 8. A Sickle Cell Scholar Component.

描述（由申请人提供）： 拟议中的华盛顿地区综合镰状细胞中心包括霍华德大学，一个历史上的黑人教学机构在国家的首都，儿童的国家医疗中心，医疗保健的首要提供者，以儿童镰状细胞病（SCD）在该地区，和血管医学分支NHLBI，一个国际公认的单位，导致在SCD的血管并发症的调查。拟议的中心还包括与尼日利亚扎里亚的Ahmadu Bello大学合作，该大学治疗许多尚未接触输血或羟基脲的SCD患者。拟议中心的主要重点是提高对SCD血管并发症的理解、预防和治疗。该项目的组成部分是： 1.一项在全身收缩压120-139 mm Hg的SCD患者中比较一氧化氮供体联合治疗与血管紧张素转换酶抑制剂或安慰剂预防肾功能不全、肺动脉高压、卒中和其他并发症的中心间II期研究。 2.一项通过超声心动图测量三尖瓣返流速度、HIV/AIDS和疟疾的作用以及调节内皮功能和粘附的候选基因中遗传多态性的作用来确定尼日利亚SCD患者肺动脉高压患病率的中心内临床研究。 3.一项患者服务研究项目，旨在确定与年龄和人口统计学匹配的对照组相比，患有SCD的婴幼儿中发育问题的患病率。 4.一个转化研究项目，旨在通过给予NAD前体烟酸来提高HDL水平，从而提高apoA-1水平，以改善内皮依赖性血管舒张。 5.行政核心。 6.临床核心，包括霍华德大学的成人和儿童镰状细胞诊所、儿童国家医疗中心的儿童镰状细胞诊所、NHLBI的成人镰状细胞诊所及其相关人员。 7.一个病人服务核心，重点是教育，社区推广，遗传咨询和诊断测试。 8.镰状细胞学者组成部分。